Claims for Patent: 9,650,441

Summary for Patent: 9,650,441

Title:	Anti-CD47 antibodies and methods of use
Abstract:	Disclosed herein are anti-CD47 antibody molecules, their manufacture and use in treating disorders associated with CD47 expression, for example, certain hematological cancers and solid tumors.
Inventor(s):	Grosveld; Frank (Rotterdam, NL), Palombella; Vito (Needham, MA), Holland; Pamela M. (Belmont, MA), Paterson; Alison (Dedham, MA), Hill; Jonathan (Salem, MA)
Assignee:	Erasmus University Medical Center (Rotterdam, NL) Surface Oncology, Inc. (Cambridge, MA)
Application Number:	15/271,861
Patent Claims:	1. A method of treating cancer in a subject in need thereof, wherein the cancer comprises cells that express CD47, the method comprising administering to the subject an effective amount of an isolated anti-CD47 antibody molecule comprising a heavy chain complementarity determining region 1 (HC CDR1) of the amino acid sequence set forth in SEQ ID NO: 7, a heavy chain complementarity determining region 2 (HC CDR2) of the amino acid sequence set forth in SEQ ID NO: 8, a heavy chain complementarity determining region 3 (HC CDR3) of the amino acid sequence set forth in SEQ ID NO: 9, a light chain complementarity determining region 1 (LC CDR1) of the amino acid sequence set forth in SEQ ID NO: 10, a light chain complementarity determining region 2 (LC CDR2) of the amino acid sequence set forth in SEQ ID NO: 11, and a light chain complementarity determining region 3 (LC CDR3) of the amino acid sequence set forth in SEQ ID NO: 12. 2. The method of claim 1, wherein the anti-CD47 antibody molecule is administered in combination with a chemotherapeutic agent or therapeutic antibody molecule. 3. The method of claim 1, wherein the anti-CD47 antibody molecule is administered in combination with an opsonizing antibody molecule. 4. The method of claim 3, wherein the opsonizing antibody molecule is an anti-CD19 antibody molecule, an anti-CD20 antibody molecule, or an anti-CD38 antibody molecule. 5. The method of claim 4, wherein the opsonizing antibody molecule is an anti-CD20 antibody molecule. 6. The method of claim 4, wherein the antibody molecule is rituximab. 7. The method of claim 1, wherein the cancer i a hematological cancer. 8. The method of claim 7, wherein the hematological cancer is selected from the group consisting of: acute lymphoblastic leukemia (ALL), T-ALL, B-ALL, acute myelogenous leukemia (AML), Non-Hodgkin lymphoma, B-lymphoblastic leukemia/lymphoma; B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), Burkitt's lymphoma, follicular lymphoma, SLL, marginal zone lymphoma, CNS lymphoma, Richter's Syndrome, multiple myeloma, myelofibrosis, polycythemia vera, cutaneous T-cell lymphoma, MGUS, myelodysplastic syndrome (MDS), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma and anaplastic large cell lymphoma. 9. The method of claim 8, wherein the hematological cancer is acute myelogenous leukemia (AML) or Burkitt's lymphoma. 10. The method of claim 1, wherein the cancer is a solid tumor. 11. The method of claim 10, wherein the cancer is a cancer of a tissue selected from the group consisting of: lung, pancreas, breast, liver, ovary, testicle, kidney, bladder, spine, brain, cervix, endometrium, colon/rectum, anus, esophagus, gallbladder, gastrointestinal tract, skin, prostate, pituitary, stomach, uterus, vagina, and thyroid. 12. The method of claim 1, wherein the anti-CD47 antibody molecule comprises a heavy chain variable region (VH) of the amino acid sequence set forth in SEQ TD NO: 4 and a light chain variable region (VL) of the amino acid sequence set forth in SEQ ID NO: 6. 13. The method of claim 1, wherein the anti-CD47 antibody molecule further comprises a wild type or mutant IgG1 heavy chain constant region. 14. The method of claim 1, wherein the anti-CD47 antibody molecule further comprises a wild type or mutant IgG4 heavy chain constant region. 15. The method of claim 14, wherein the IgG4 heavy chain constant region comprises one or both of the substitutions S228P and L235E. 16. The method of claim 1, wherein the anti-CD47 antibody molecule comprises a heavy chain of the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 23, SEQ ID NO: 24, or SEQ ID NO: 25, and a light chain of the amino acid sequence set forth in SEQ ID NO: 16 or SEQ ID NO: 26. 17. The method of claim 1, wherein the anti-CD47 antibody molecule is administered in combination with a pharmaceutically acceptable carrier or diluent. 18. The method of claim 1, wherein the anti-CD47 antibody molecule is administered subcutaneously. 19. The method of claim 1, wherein the anti-CD47 antibody molecule is administered intravenously. 20. The method of claim 1, wherein the cancer is selected from the group consisting of: pancreatic cancer, ovarian cancer, breast cancer, stomach cancer, colon cancer, prostate cancer, and uterine cancer.

Details for Patent 9,650,441

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2035-09-21
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2035-09-21
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2035-09-21